Supernus Pharmaceuticals, Inc. - Common Stock (SUPN)

Supernus Pharmaceuticals (NASDAQ:SUPN) and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing 12-month net revenue as of June 30, 2026.

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401 common shares of Indivior for each share of Supernus.

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 3...

ROCKVILLE, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the second quarter 2026 and associated Company developments.

ROCKVILLE, Md. and RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that they have entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction to create a leading diversified, central nervous system (CNS) biopharmaceutical company with significant scale. The transaction is expected to generate significant value for stockholders of both companies, realizing $125 million in expected annual cost synergies. The combined entity will be named Supernus, Inc. and will be listed on the Nasdaq Global Market under the ticker symbol “SUPN”. Upon completion of the transaction, Jack Khattar, Supernus Pharmaceuticals President and Chief Executive Officer, will serve as President, Chief Executive Officer and a member of the Board of Directors of the combined company, and Tony Kingsley, a member of Indivior’s Board of Directors, will serve as Board Chair of the combined company.

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting results this Tuesday after market hours. Here’s what to look for. S...

ROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...

ROCKVILLE, Md., July 14, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, celebrates the five-year anniversary of the U.S. Food and Drug Administration (FDA) approval of Qelbree (viloxazine extended-release capsules) for attention-deficit/hyperactivity disorder (ADHD). Since its initial approval for pediatric (6 to 17 years) ADHD in April 2021, and subsequent approval for adults in April 2022, Qelbree has served as a valuable option for the nearly 16 million adults and 7 million children and teens living with ADHD in the U.S.,1,2 showcasing Supernus’ 25+ year legacy in ADHD research.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $43.79, producing a disappointing 9.4% loss - a stark contrast to the S&P 500’s 9.3%...

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following June investor conferences:

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...

Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide.

Supernus Pharmaceuticals’ first quarter saw a positive market response, as management attributed the revenue growth to robust demand for its key growth produ...

What Happened? Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 6.8% in the afternoon session after the company repor...

ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV.

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 38.6% year on yea...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged...